The immunomodulator FTY720 is phosphorylated and released from platelets - PubMed (original) (raw)
. 2007 Jul 30;568(1-3):106-11.
doi: 10.1016/j.ejphar.2007.04.053. Epub 2007 May 22.
Affiliations
- PMID: 17553484
- DOI: 10.1016/j.ejphar.2007.04.053
Free article
The immunomodulator FTY720 is phosphorylated and released from platelets
Yoshihiro Anada et al. Eur J Pharmacol. 2007.
Free article
Abstract
The novel immunomodulator FTY720 causes lymphocytes from peripheral blood to accumulate in lymphoid tissues. In vivo, FTY720 is phosphorylated to FTY720-P, which binds to the sphingosine 1-phosphate receptor S1P(1). So far, it has been unclear where FTY720-P is produced. We demonstrate that platelets efficiently convert FTY720 to FTY720-P and release it into the extracellular space. This release is mostly independent of platelet activation, but is slightly increased upon thrombin stimulation. These results suggest that platelets are a major source of plasma FTY720-P, and that FTY720-P release is mediated by two different transporters.
Similar articles
- Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
Kihara A, Igarashi Y. Kihara A, et al. Biochim Biophys Acta. 2008 Sep;1781(9):496-502. doi: 10.1016/j.bbalip.2008.05.003. Epub 2008 Jun 13. Biochim Biophys Acta. 2008. PMID: 18555808 Review. - Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
Sensken SC, Bode C, Gräler MH. Sensken SC, et al. J Pharmacol Exp Ther. 2009 Mar;328(3):963-9. doi: 10.1124/jpet.108.148163. Epub 2008 Dec 12. J Pharmacol Exp Ther. 2009. PMID: 19074680 - FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EA. Nofer JR, et al. Circulation. 2007 Jan 30;115(4):501-8. doi: 10.1161/CIRCULATIONAHA.106.641407. Epub 2007 Jan 22. Circulation. 2007. PMID: 17242282 - Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW, Choi JW, Chun J. Lee CW, et al. Arch Pharm Res. 2010 Oct;33(10):1567-74. doi: 10.1007/s12272-010-1008-5. Epub 2010 Oct 30. Arch Pharm Res. 2010. PMID: 21052934 Review.
Cited by
- Granule-mediated release of sphingosine-1-phosphate by activated platelets.
Jonnalagadda D, Sunkara M, Morris AJ, Whiteheart SW. Jonnalagadda D, et al. Biochim Biophys Acta. 2014 Nov;1841(11):1581-9. doi: 10.1016/j.bbalip.2014.08.013. Epub 2014 Aug 23. Biochim Biophys Acta. 2014. PMID: 25158625 Free PMC article. - Experimental cerebral malaria pathogenesis--hemodynamics at the blood brain barrier.
Nacer A, Movila A, Sohet F, Girgis NM, Gundra UM, Loke P, Daneman R, Frevert U. Nacer A, et al. PLoS Pathog. 2014 Dec 4;10(12):e1004528. doi: 10.1371/journal.ppat.1004528. eCollection 2014 Dec. PLoS Pathog. 2014. PMID: 25474413 Free PMC article. - Sources, metabolism, and regulation of circulating sphingosine-1-phosphate.
Książek M, Chacińska M, Chabowski A, Baranowski M. Książek M, et al. J Lipid Res. 2015 Jul;56(7):1271-81. doi: 10.1194/jlr.R059543. Epub 2015 May 26. J Lipid Res. 2015. PMID: 26014962 Free PMC article. Review. - Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells.
Hisano Y, Kobayashi N, Yamaguchi A, Nishi T. Hisano Y, et al. PLoS One. 2012;7(6):e38941. doi: 10.1371/journal.pone.0038941. Epub 2012 Jun 12. PLoS One. 2012. PMID: 22723910 Free PMC article. - Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes.
Yonesu K, Kubota K, Tamura M, Inaba S, Honda T, Yahara C, Watanabe N, Matsuoka T, Nara F. Yonesu K, et al. J Biol Chem. 2011 Jul 15;286(28):24765-75. doi: 10.1074/jbc.M110.217299. Epub 2011 May 25. J Biol Chem. 2011. PMID: 21613209 Free PMC article.